Zhaohui Su: EMA’s Vision for Better Randomized Trials and Real-World Evidence
Zhaohui Su/LinkedIn

Zhaohui Su: EMA’s Vision for Better Randomized Trials and Real-World Evidence

Zhaohui Su, VP, Strategic Consulting at Veristat, shared a post on LinkedIn:

“One of the most concise and forward-looking articles on the future of clinical evidence outlines 6 principles for 2030 as defined by EMA and EU regulators:

– Patient voice at the center of every decision.
– Existing data and knowledge inform new studies.
– Clear research questions drive study design.
– Better randomized controlled trials (RCT) and validated real-world evidence (RWE) across the full spectrum.
– Early, collaborative planning across stakeholders.
– Transparency builds trust.

This presents a refreshingly clear direction for the field. Enjoy the read. What resonates most with you?

Please feel free to leave comments or reach out to Veristat for a conversation about how we may help your studies.”

Other articles featuring Zhaohui Su on OncoDaily.